Nauta, J. F.
Santema, B. T.
van der Wal, M. H. L.
Koops, A.
Warink-Riemersma, J.
van Dijk, K.
Inkelaar, F.
Prückl, S.
Suwijn, J.
van Deursen, V. M.
Meijers, W. C.
Coster, J.
Westenbrink, B. D.
de Boer, R. A.
Hummel, Y.
van Melle, J.
van Veldhuisen, D. J.
van der Meer, P.
Voors, A. A.
Article History
Accepted: 27 May 2021
First Online: 14 June 2021
Conflict of interest
: The University Medical Centre Groningen, which employs all the authors of this article, has received research grants and/or consultancy fees from Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Cytokinetics, Merck, Myokardia, Novartis, Novonordisk and Roche Diagnostics. A.A. Voors has received consultancy fees from Myokardia, Bayer, AstraZeneca, Merck and Boehringer Ingelheim. P. van der Meer reports personal fees from Pfizer, Vifor Pharma, Novartis and Servier. R.A. de Boer received personal fees from Abbott, AstraZeneca, MandalMed Inc, Novartis and Roche. D.J. van Veldhuisen reports board membership fees/travel expenses from Johnson & Johnson and Novartis. J.F. Nauta, B.T. Santema, M.H.L. van der Wal, A. Koops, J. Warink-Riemersma, K. van Dijk, F. Inkelaar, S. Prückl, J. Suwijn, V.M. van Deursen, W.C. Meijers, J. Coster, B.D. Westenbrink, Y. Hummel and J. van Melle declare that they have no competing interests.